Linsitinib Not Effective for Adrenocortical Carcinoma

Share this content:
Linsitinib did not improve overall survival in patients with locally advanced or metastatic adrenocortical carcinoma.
Linsitinib did not improve overall survival in patients with locally advanced or metastatic adrenocortical carcinoma.

According to a new study published online in the journal The Lancet Oncology, researchers have found that linsitinib, an IGF-1R and insulin receptor inhibitor, did not improve overall survival in patients with locally advanced or metastatic adrenocortical carcinoma.

Previous studies have shown that linsitinib has anti-tumor activity and acceptable tolerability in patients with adrenocortical adenocarcinoma, so researchers sought to compare its efficacy versus placebo in patients with advanced adrenocortical carcinoma.

For the international, double-blind, placebo-controlled phase 3 study, researchers enrolled 139 patients with advanced adrenocortical carcinoma, a rare, aggressive cancer that lacks many treatment options, and assigned 90 of whom to linsitinib and 49 to placebo. Patients in the linsitinib group received linsitinib 150mg orally twice daily.

RELATED: Treating Hypercalcemia in Patients with Cancer

Results showed that there was no difference in overall survival between linsitinib and placebo (median 323 days; 95% CI: 256 - 507 vs 365 days; 95% CI: 249 - 556; HR = 0.94; P = 0.77). There were 92 deaths in total during the study.

In regard to safety, the most common severe adverse events associated with linsitinib were fatigue, nausea, and hyperglycemia.

Because linsitinib did not increase overall survival compared with placebo, the researchers cannot recommend linsitinib as treatment for patients with advanced adrenocortical carcinoma.

Reference

  1. Fassnacht M, Berruti A, Baudin E, et al. Linsitinib (OS-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015. [Epub ahead of print]. doi: 10.1016/S1470-2045(15)70081-1.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters